Close Menu

NEW YORK – Guardant Health this week closed a previously announced underwritten public offering of 13,225,000 shares of its common stock, at a price of $84.00 per share. Guardant sold 4,312,500 of the total shares and SoftBank Investment Advisers sold the remainder, with JP Morgan Securities acting as sole book-running manager.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.